The 21st century is the century of bioengineering. Whoever gets the first chance wins the future. In 2000, aiming at the sunrise industry of bioengineering, Mao Jinwu (The Chairman of Board）resolutely resigned from the post of head of Yueyang central blood station when his official career was smooth, and entered the commercial sea, choosing a more challenging lifestyle.
In 20 years, guided by the banner of independent innovation, Mao Jinwu has built Hunan RunKun Pharmaceutical Co., Ltd. into a national high-tech enterprise that enjoys a high reputation in Hunan Province and even in the central and southern regions and is dedicated to the development of biopharmaceutical and medical equipment industries. RunKun Pharmaceutical Co., Ltd. has been involved in the capital market for 10 years. It was listed as a backup enterprise in Hunan Province in 2018 and listed on the science and Technology Innovation Board of Hunan regional equity market in 2020.
In the middle of May 2020, initiated by Hunan equity exchange, experts from Hunan Equity Investment Association, Hunan Medical Investment Fund and other units were specially invited to participate in the activity of "looking for shares of Hunan merchants", and entered Hunan RunKun Pharmaceutical Co., Ltd., one of the first 16 enterprises in the scientific and technological innovation panel of Hunan regional equity market
Dare to be the first to innovate and develop independently
Dare to be the first, dare to fight, dare to fight, and compete with the world's best, is the key to the development of enterprises. Major scientific research achievements of Kangrun pharmaceutical industry: hepatitis C virus antigen detection kit, hepatitis C virus antigen antibody joint detection kit, perfluoropropane human albumin microspheres injection, recombinant staphylokinase, wireless handheld color ultrasound imaging system and other products are all independently innovated and developed.
Mao Jinwu, Chairman of RunKun pharmaceutical, was interviewed.
This year's performance is expected to exceed 200 million yuan
The company has undertaken national "863" plan, major new drug creation, special project of central government guiding local science and technology development, special project of national strategic emerging industry protein biological medicine development, and major national science and technology projects of manufacturing province. At present, the company has more than 30 products under research to be listed, 28 authorized patents and 4 software copyrights.
The SARS-CoV-2 IgM/IgG antibody test kit developed by RunKun Pharmaceutical Co., Ltd.
After the outbreak of the COVID-19,The SARS-CoV-2 IgM/IgG antibody detection kit was successfully developed in mid February. In March, it obtained the EU CE certification. In May, it entered China's medical and health products import and Export Chamber of Commerce to obtain the foreign standard certification or registration of medical material production enterprises list.
The Test kit has five characteristics of fast, intuitive, convenient, accurate and economic. It can produce results within 10 minutes, and can be judged by naked eyes. It does not need detection equipment and other site requirements. Combined nucleic acid detection can reduce false negative results, and the price is only 1 / 4-1 / 5 of the new coronary pneumonia virus nucleic acid detection kit.
Wireless Handheld Color Doppler Ultrasound, where the wind and waves are highest
"Our handheld ultrasound products are the first in China to get the registration number. This is a revolutionary product. Experts predict that the market will break out in two years Mao Jinwu introduced that, in short, this product is to turn the doctor's "Stethoscope" into a "visualizer". Every paramedic can have one in their pocket without any side effects. Diagnosis of disease can be seen, treatment process can be seen, treatment results can be seen, blood vessels can not be found, surgical nerves can not be found, and the effect of gravel can be seen. It can be said that it is a diagnostic product and an auxiliary treatment product.
Scientific researchers of RunKun pharmaceutical are demonstrating "wireless handheld color ultrasound equipment"
The research team found that this wireless handheld Color Ultrasound product has a price advantage over the just in case conventional ultrasound equipment. But limited by the medical procurement system, it is difficult to promote in the hospital market. But the good news is that with the development of Internet medicine and medical consortia, the market space of "hand-held B-ultrasound" is gradually opening.
To build a platform for pharmaceutical intelligent manufacturing industry
The high-end medical device intelligent manufacturing industrial park planned by RunKun Pharmaceutical Co., Ltd. has a total investment of about 1 billion yuan, 1000 enterprises (products) are connected, and the output value of the platform is 5 billion yuan and the profit and tax are 500 million yuan five years after the platform is put into operation. More than 2000 jobs have been created, more than 200 talents of intelligent technology and health technology have been cultivated every year, and China's first pharmaceutical industry 4.0 Intelligent Manufacturing Industrial Park has been built.
RunKun pharmaceutical said that it is expected to preliminarily complete the industrial integration in 2021, with a revenue of 250 million yuan and a net profit of more than 40 million yuan in 2021, and strive to be listed on the science and technology innovation board or the growth enterprise board in 2023.
In March 2020, RunKun Pharmaceutical Co., Ltd. was among the first batch of enterprises in science and technology innovation special edition of Hunan Province.
In this regard, Mao Jinwu also admitted that after the company landed on the "science and Technology Innovation Board" of Hunan stock exchange this year, the company's business structure urgently needed strategic adjustment. In the near future, it is planned to invite investment banks of securities companies and industry experts to jointly control the company's strategy. In the future, it is necessary for RunKun pharmaceutical industry to focus on building a special medical device sector with diagnostic reagent products as the main body, hand-held ultrasound, raw material platform and R & D platform, in order to obtain the value recognition of the capital market.